Introduction
Typhoid fever, caused by infect ion with Salm onella typhi, r emains an impor tant health pr oblem in many part of t he wor ld, wit h an est imat ed annual incidence of about 16 million cases and 600,000 deat hs [15] . Typhoid fever can be occurred throughout the year in Korea, especially in summer , and is char act er ized by the clinical sympt oms such as t yphoid fever , abdominal pain, and diar r hea. Mort alit y rat es for t yphoid fever of up t o 30% have been r epor t ed fr om some developing countr ies [1, 4, 9, 12] .
In the past , chloramphenicol and ampicillin have been effect ively used for many year s, but t r eatment and cont rol of t yphoid fever has become incr easingly difficult because st r ains of S . typhi r esist ant t o these ant ibiotics have been emer ged worldwide [27] . Typhoid vaccines composed of inact ivat ed cells of S. typhi wer e developed early in the 20th cent ur y based on principles ar t iculat ed by Past eur , but t hey were recent ly not used because t he vaccine can be att acked with a undesirable disease such as high typhoid fever, wholecell vaccines are only up to 70% effective, and the immunit y does not per sist for mor e t han t hree to five year s [2, 3, 14, 15] Ger manier et al have isolat ed a mut ant S . typhi st r ain, Ty21a t hat has been used as an orally administ ered, at tenuat ed vaccine. St r ain Ty21a has lost an epimerase capable of convert ing glucose to galactose, a loss resulting in defect ive synt hesis of the polysaccharide component of LPS. As a r esult Ty21a is not well adapt ed t o survive and mult iply in t he int estinal t r act [7] . In t hese days, parent er al vaccine, which made of pur ified Vi capsular polysacchar ide have been widely used [6, 7] . Vi polysaccharide is a wellst andar dized ant igen that is effect ive in a single par ent er al dose, is safer t han whole-cell vaccine [24] . Hessel et al showed t hat a vaccine composed of purified Vi capsular polysacchar ide of S. typhi, given as a single int r amuscular or deep subcutaneous injection, has consistent immunogenicit y and efficacy, and side effect s wer e infr equent and mild [11] . This exper iment was conduct ed to ident ify the immunit y of mice pr event ed wit h pur ified Vi polysacchar ide, submitt ed fr om Greencross Company, based on Guideline for st andard and t est pr ocedur e of biological mat er ials, r ecommended by Korean Food & Drug Administ rat ion [8] .
Materials and Methods

Challe nging organism
S alm onella typhi ty2 offer ed fr om Kor ean Nat ional Instit ute of Health was used as challenging or ganism. The bact er ium was subcultur ed twice in tr ypt ic soy agar (Difco, USA) and tr ypt ic soy broth (Difco, USA), and used in t he st udy aft er counted by plat e count technique.
Anim als
Four week-old SPF male BALB/c mice wer e pr ovided fr om Samt ako (Kor ea). The animals wer e kept in plastic cages (polycar bonat e, 222713 Cm) at 22 in negat ive r ack (Thr ee shine, Kor ea) wit h hepafilter . Animal food (CRF-1, Char les r iver , Japan) and wat er wer e pr ovided ad libitum . Aft er accommodat ion per iod of one week, t he animals wer e used in t he st udy.
Efficacy of Purified Vi
Lethal dose 50 (LD 50)
Based on Guideline for st andar d and test pr ocedur e of biological mat erials, r ecommended by Kor ean Food & Dr ug Administr aion [8] , the challenging or ganism must be below 20 bact er ia in LD50 value. In order t o assess LD50, S . typhi ty2 was dilut ed in 5% mucin wit h concent r at ions of 1000, 100, 10, 1 CFU/0.5ml. Ten mice of each gr oup wer e int r aperit oneally administ er ed wit h the challenging or ganism, and then mor talit y was evaluated for thr ee days. LD50 was calculated wit h Trimmed Spearman-Kar ber met hod [10] .
Effective dose 50 (ED 50)
Typhoid vaccine was dilut ed wit h st er ilized phosphat e buffered saline (PBS, pH 7.2) wit h concent r at ion of 0.25, 0.05, 0.01, and 0.002 /0.5ml and fift een mice of each group wer e int raper it oneally administer ed wit h the dilut ed vaccine of each concent ration. Aft er 12 post-inoculation days, t en mice of each gr oup were inoculat ed wit h challenging or ganisms of 1000 CFU/0.5ml, and mor talit y was evaluated for t hr ee days. ED50 was obt ained wit h Pr obits methods (Quantal Dose-Response, Phar macologic Calculation SystemVer sion 4.1).
Enzym e linked im m unosorbent assay
To evaluat e t he antibody t it er against Vi ant igen, mice sera were collect ed t hr ough abdominal vein at 12 days post immunizat ion. Salm onella typhi t y2 cult ur ed in t r yptic soy br oth wer e collect ed and washed t hr ee t imes with sterilized PBS and cr ushed with sonicator . Five g of t otal bact er ial pr ot ein was loaded int o each well of ELISA plate and incubated at 4 overnight . After washed t hr ee t imes wit h PBS, t he plate was blocked wit h 1% bovine serum albumin at 4 for 2 hr and incubated wit h sera (1:50 diluent s) of all mice t r eated and unt r eated wit h t he vaccine at room t emper at ur e for 2 hr . Then it was washed and incubated wit h HRP-conjugat ed ant i mouse IgG ant ibodies (Pr omega, USA) at RT for 1 hr . Finally it was washed and visualized wit h o-phenylenediamine dihydr ochlor ide (Sigma, USA) and t he absor bance was measur ed at 450 nm wavelengt h.
Western blot
The sonicat ed cells wer e suspended in 2% SDS and pr ot eins wer e ext r act ed by boiling for 10 min. Then t he pr ot ein was mixed with sample buffer (0.1 M Tris-HCl, pH 6.8, 10% Glycerol, 2% SDS, 5% 2-mer capt oethanol, 0.05% br omophenol blue) and boiled for 5 min. It was separ at ed on 12.5% polyacrylamide gel at 200 V (BioRad, USA) for 45 min and transferred to nitrocellulose membrane at 100 V for 1 hr . Aft er t ransferr ed, t he membrane was blocked wit h 5% skim milk at 4 for 2 hr and incubat ed with each serum of a mouse (1:100 diluents) administ er ed wit h 0.25 / 0.5ml of t yphoid vaccine and a cont r ol mouse at 4 overnight . Aft er washed, it was react ed wit h HRP-conjugat ed ant i mouse IgG antibodies (Pr omega, USA) at room t emper ature for 1 hr and visualized with 3, 3'-diaminobenzidine (Vector, USA).
Results
LD 50
When calculat ed with Tr immed Spear man-Kar ber met hod, LD50 of challenging or ganism was 6.31 CFU/mouse, and we consider ed that t he bact er ium was suitable for t his st udy (Table 1) . 
ED 50
When calculat ed with Probit s met hod, ED50 of t yphoid vaccine was 0.016 /mouse (Table 2) .
ELISA
Ser a of five mice of each gr oup wer e used t o evaluat e t he antibody level for Vi ant igen. The r esult s showed that antibody level was higher in mice t r eated wit h vaccine t han in untr eat ed mice. In mice group (0.5097 0.0606) t r eated wit h high dose (0.25 /0.5ml) vaccine, ant ibody level t o Vi antigen was 4 t imes as in contr ol mice (0.1113 0.0110) (Fig 1) . When t itr at ion was evaluated with serum of a mouse showing middle value in each gr oup, a significant positive r eact ion was ident ified up t o a dilut ed concent r at ion of 1:320 in 0.25 /0.5ml t r eated mouse, 1:160 in 0.05 /0.5ml, 1:80 in 0.01 /0.5ml, and 1:40 in 0.002 /0.5ml (Fig 2) . 
Western blot analysis
Six major pr otein bands of about 66, 55, 35, 33, 18, and 9 kd wer e detected using a mouse serum tr eat ed wit h 0.25 /0.5ml of t he vaccine, wher eas only one weak band of about 35 kd in a contr ol mouse was detect ed. The pr otein band of 35kd was considered as nonspecific r eaction (Fig 3) . 
Discussion
S alm onella typhi is gr am-negat ive bact er ium that belongs to the Enterobacteriaceae family. The bacterium is encapsulated by a polysacchar ide layer and has following t hr ee major prot eins: ) t he capsular polysacchar ide or Vi ant igen; ) the O or somatic antigen (cell-wall lipopolysaccharide), which corr esponds to the endot oxin; and ) t he H or flagellar antigen, which is a pr ot ein. S. typhi is distinct ive among t he Salm onella spp. in possessing t he Vi ant igen, alt hough it is found in lower quantit ies in some st r ains of S . paratyphi C and S . dublin [15] . Vaccines t hat cont ain purified capsular polysacchar ide ant igens elicit ser um ant ibodies t hat provide type-specific protection against invasive infect ions. The whole organism is not r equir ed t o elicit t his pr otect ive immune r esponse. Vaccination wit h t he Vi antigen alone elicits a much great er and mor e consist ent Vi ant igen antibody r esponse t han whole-cell vaccinat ion [20, 21, 25] .
Since t he Vi ant igen of S. typhi was fir st ident ified by Felix and Pit t [5] , many st udies about t yphoid vaccine have been conduct ed [18, 19, 26, 28] . The Vi ant igen physically prevents ant ibodies binding t o t he O ant igen and is also associat ed wit h inhibit ion of complement act ivat ion as well as wit h r esist ance to complement -mediat ed lysis and phagocytosis [22, 26] . Thus, the Vi antigen allows S . typhi to sur vive in t he blood, leading t o sept icemia. Specific ser um antibody t o Vi ant igen is necessar y to act ivat e complement against S. typhi.
The Vi polysaccharide vaccine has been used in many par t of wor ld, and is administ er ed in one dose of 25 /0.5ml as an int r amuscular or deep subcutaneous infect ion, with revaccinat ion after 3 year s r ecommended for individuals who remain at risk of infect ion [11] .
In pot ency test using mice, mixt ur e of challenging or ganism and mucin solution has been administered, which is to increase toxicit y of t he or ganism [23, 25] . By using t he same method, t his st udy could be effect ively conduct ed.
Many studies about safet y and immunogenicit y of Vi vaccine have been repor t ed in adult s or childr en. In Sout h Africa, Keddy et al. revealed t hat Vi vaccinat ion has led to ongoing ant ibody pr oduction in great er t han 50% of Vi vaccinat ed childr en in an endemic ar ea for a per iod of 10 year s [16] . According t o Kim et al. of 137 vaccinees, 116 (84.7%) maint ained a per sistent rise in Vi ant ibody t it er 12 mont hs aft er vaccination, and 55 out of 100 (55.0%) had a 4-fold or great er r ise at 36 mont hs [17] . In our study, only one dose of 0.25 /0.5ml of Vi polysaccharide vaccine, submitt ed fr om Gr eencross co., successfully could prevent let hal event in mice. To evaluate more pr ecise effect in humans of Vi vaccine, clinical t r ial is to be conduct ed.
